Hair loss affects millions of men worldwide, yet treatment options have remained largely unchanged for over 30 years. That may finally be set to change.
Cosmo Pharmaceuticals recently made headlines after reporting positive results from late-stage clinical trials of its experimental hair-loss treatment, causing the company’s share price to surge by 40%.
The drug, known as clascoterone 5% topical solution, works by blocking the hormone dihydrotestosterone (DHT) directly at the scalp — the key driver of male-pattern baldness. Unlike traditional oral medications, which alter hormone levels throughout the body, clascoterone targets the scalp locally.
While early trial results have generated excitement among investors and patients, dermatologists advise a cautious approach.
“Clascoterone offers meaningful benefits, but it is not a miracle cure,” says Dr. Abhishek Pilani, Founder of Assure Clinic and MD Dermatology.
How the New Drug Works
Clinical trials suggest clascoterone can slow hair loss and improve hair thickness, particularly in individuals with early-stage thinning. However, experts stress that its primary benefit lies in stabilizing hair loss rather than producing dramatic regrowth.
The treatment strengthens weakened follicles but does not revive completely dormant or dead ones. Visible regrowth is more likely where follicles are miniaturized but still active, while fully bald or scarred areas are unlikely to respond. Dermatologists describe the drug as a “maintenance-plus” option — helpful for preserving existing hair and modestly improving density, but not reversing advanced baldness.
Comparison With Existing Treatments
Minoxidil and finasteride remain the most commonly used hair-loss therapies. Minoxidil enhances blood flow to follicles, while finasteride inhibits DHT production systemically.
Clascoterone works differently by blocking DHT locally at the scalp, targeting the root cause while potentially minimizing whole-body exposure. Early indications suggest its effectiveness in early hair loss may be comparable to finasteride, though minoxidil still has more evidence supporting visible regrowth. Many specialists suggest combining treatments for optimal results.
Safety and Side Effects
Clinical trials report mostly mild side effects, including scalp redness, itching, dryness, or irritation, which are typically temporary.
Because the drug is applied topically, systemic side effects — such as sexual or mood-related issues linked to oral finasteride — appear to be minimal. However, long-term safety data is limited, and medical supervision is recommended, particularly for younger patients likely to use the treatment for many years.
Who Should Use It
Ideal candidates include men with early to moderate androgenetic alopecia, where follicles are still active, or those unable to tolerate oral finasteride.
The treatment is not suitable for advanced baldness, where follicles are nonfunctional. Individuals with scalp infections, severe skin conditions, hormonal disorders, or those planning pregnancy should avoid use unless advised by a physician. A proper diagnosis is essential before starting any hair-loss therapy.
Expectations and Treatment Duration
Hair growth is gradual. Most users should not expect visible improvement before 3 to 4 months, with clearer results typically appearing around six months.
If treatment is discontinued, benefits usually fade within 3 to 6 months, and hair loss may resume. Like other hormonal therapies, clascoterone is not a permanent cure and requires long-term, consistent use to maintain results.
Cosmo Pharmaceuticals’ new hair-loss drug represents a fresh approach after decades of limited innovation. For the right patient, used early and consistently, it could become a valuable addition to existing treatment options.
However, dermatologists emphasize managing expectations: this is not a miracle solution, but a scientifically backed tool that works best as part of a long-term hair management plan under medical supervision.
